Brauchen wir Magensäure?

Schlüsselwörter

Magensäure - Säurebarriere - Protonenpumpeninhibitoren

Keywords

gastric acid - acid barrier - proton pump inhibitors

• Literatur

• 1 Agunod M, Yamaguchi N, Lopez R et al. Correlative study of hydrochloric acid, pepsin, and intrinsic factor secretion in newborns and infants. Am J Dig Dis 1969; 14: 400-414
• 2 Bajaj JS, Zadvornova Y, Heuman DM et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol 2009; 104: 1130-1134
• 3 Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 2011; 34: 1269-1281
• 4 Charman WN, Porter CJ, Mithani S et al. Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharma Sci 1997; 86: 269-282
• 5 Dial S, Delaney JA, Barkun AN et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294: 2989-2995
• 6 Dressman JB, Berardi RR, Dermentzoglou LC et al. Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm Res 1990; 7: 756-761
• 7 Evenepoel P, Claus D, Geypens B et al. Evidence for impaired assimilation and increased colonic fermentation of protein, related to gastric acid suppression therapy. Aliment Pharmacol Ther 1998; 12: 1011-1019
• 8 Feldman M, Cryer B, McArthur KE et al. Effects of aging and gastritis on gastric acid and pepsin secretion in humans: a prospective study. Gastroenterology 1996; 110: 1043-1052
• 9 Garcia Rodriguez LA, Ruigomez A. Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk?. Epidemiology 1997; 8: 571-574
• 10 Gray SL, LaCroix AZ, Larson J et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med 2010; 170: 765-771
• 11 Harder H, Teyssen S, Stephan F et al. Effect of 7-day therapy with different doses of the proton pump inhibitor lansoprazole on the intragastric pH in healthy human subjects. Scand J Gastroenterol 1999; 34: 551-561
• 12 Howell MD, Novack V, Grgurich P et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010; 170: 784-790
• 13 Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep 2010; 12: 448-457
• 14 Keller J, Spranger H, Henniges UM et al. Nüchtern vor Magenspiegelung: sinnvoll oder Schikane?. Z Gastroenterol 2008; 46: 1
• 15 Koopmans M, Duizer E. Foodborne viruses: an emerging problem. Int J Food Microbiol 2004; 90: 23-41
• 16 Laheij RJ, Van Ijzendoorn MC, Janssen MJ et al. Gastric acid-suppressive therapy and community-acquired respiratory infections. Aliment Pharmacol Ther 2003; 18: 847-851
• 17 Layer P, Holst JJ, Grandt D et al. Ileal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. DigDis Sci 1995; 40: 1074-1082
• 18 Linsky A, Gupta K, Lawler EV et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med 2010; 170: 772-778
• 19 Lombardo L, Foti M, Ruggia O et al. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2010; 8: 504-508
• 20 Martinsen TC, Benestad SL, Moldal T et al. Inhibitors of gastric acid secretion increase the risk of prion infection in mice. Scand J Gastroenterol 2011; 46: 1418-1422
• 21 Martinsen TC, Bergh K, Waldum HL. Gastric juice: a barrier against infectious diseases. Basic Clin Pharmacol Toxicol 2005; 96: 94-102
• 22 Mat Saad AZ, Collins N, Lobo MM et al. Proton pump inhibitors: a survey of prescribing in an Irish general hospital. Int J Clin Pract 2005; 59: 31-34
• 23 Schroder-Bernhardi D, Roth K, Dietlein G. Off-label use of proton pump inhibitors and P-blockers in general practices: an analysis using the Disease Analyzer–mediplus patient database. International journal of clinical pharmacology and therapeutics 2004; 42: 581-588
• 24 Targownik LE, Lix LM, Leung S et al. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010; 138: 896-904
• 25 Waldum HL, Brenna E, Sandvik AK. Long-term safety of proton pump inhibitors: risks of gastric neoplasia and infections. Expert opinion on drug safety 2002; 1: 29-38
• 26 Zeidler M, Ironside JW. The new variant of Creutzfeldt-Jakob disease. Rev Sci Tech 2000; 19: 98-120